How does Sitagliptin impact inflammation markers in patients with comorbidities, and what are the broader implications for systemic health?
Sunil JoshiExplorer
How does Sitagliptin impact inflammation markers in patients with comorbidities?
Share
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Sitagliptin reduces inflammation markers like CRP and IL-6 in diabetic patients, potentially lowering cardiovascular risks.